Overview

Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Proof of concept study to assess the safety and tolerability of AX-158 in patients with mild to moderate psoriasis. Patients will be evaluated for a 28-day treatment period with either AX-158 or Placebo and then followed for an additional 30 days for safety.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Artax Biopharma Inc